CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia

Journal of Medical Genetics

Volumn 36, Issue 6, 1999, Pages 490-493

  Ruiz, Anna ^a   Puig, Susana ^b   Malvehy, Josep ^b   Lázaro, Conxi ^a   Lynch, Michael ^a   Gimenez Arnau, Anna M ^c   Puig, Lluis ^b,d   Sánchez Conejo, Julian ^e   Estivill, Xavier ^a   Castel, Teresa ^b  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

CDK4; CDKN2A; Cutaneous malignant melanoma; p16

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P16;

ARTICLE; CHROMOSOME 9P; DISEASE ASSOCIATION; DYSPLASTIC NEVUS; EXON; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC LINKAGE; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN VARIANT; SKIN TUMOR; SPAIN;

CARRIER PROTEINS; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DYSPLASTIC NEVUS SYNDROME; FEMALE; GERM-LINE MUTATION; HUMANS; MALE; MELANOMA; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; SKIN NEOPLASMS; SPAIN;

EID: 0033062279     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Clark WH, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions. Arch Dermatol 1978;114:732-8.
2. Cannon-Albright LA, Meyer LJ, Goldgar DE, et al. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 1994;54:6041-4.
3. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-22. Science 1992;258:1148-52.
4. Fountain JW, Karayiorgou M, Ernstoff MS, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 1992;89:10557-61.
5. Goldstein AM, Goldin R, Dracopoii NC, Clark WH Jr, Tucker MA. Two-locus linkage analysis of cutaneous malignant melanoma/dyspiastic nevi. Am J Hum Genet 1996;58:1050-6.
6. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
8. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
9. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
10. Ranade K, Hussussian CJ, Sikorsi RS, et al. Mutations associated with familial melanoma impair p16ink4 function. Nat Genet 1995;10:114-16.
11. Kamb A, Shattuck-Eidens, Eeles R, et al. Analysis of the p16 gene (CDKN2A) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:22-6.
12. Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16ink4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-9.
13. Soufir N, Avril MF, Chompret A, Demenais F, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 1998;7:209-16.
14. Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple melanomas. N Eng J Med 1998;338:879-87.
15. Ruiz A, Puig S, Lynch M, Castel T, Estivill X. Retention of the CDKN2A locus and low frequency of point mutations in primary and metastatic malignant melanoma. Int J Cancer 1998;76:312-16.
16. Puig S, Ruiz A, Castel T, et al. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (p16INK4A) gene. Hum Genet 1997;101:359-64.
17. nk4 CDK inhibitory activity. Int J Cancer 1996;66:249-54.
18. Ghiorzo P, Mantelli M, Ciotti P, et al. Italian melanoma prone families: analysis of CDKN2A/p16 mutations and linkage to 9p21. Am J Hum Genet Suppl 1996;59:A68.
19. Dracopoli NC, Fountain JW. CDKN2A mutations in melanoma. Cancer Surv 1996;26:115-32.
20. Fitzgerald MG, Harkin DP, Silva-Arrieta S, et al. Prevalence of germ-line mutations in p165 p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 1996;93:8541-5.
21. Platz A, Hansson J, Mansson-Brahme E, et al. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997;89:697-702.
22. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998;2:670-82.
23. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
24. Quelle DE, Cheng M, Ashmun RA, Sherr CJ. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci USA 1997;94:669-73.
25. Liu L, Goldstein AM, Tucker MA, et al. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF. Genes Chrom Cancer 1997;19:52-4.
26. Harland M, Meloni R, Gruis N, et al. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 1997;12:2061-7.